Merck KGaA (MRK.DE) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $68.80B | Exchange | XETRA |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | DE | CEO | Kai Beckmann |
| IPO Date | 1998-06-26 | CAGR | 4.66% |
| Employees | 62,136 | Website | www.merckgroup.com |
| Div. Yield | 1.69% | Payout Ratio | 44% |
| Buy Back Yield | — | Total Yield | 1.69% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $84.21B | P/E | 16.28 | Forward P/E | 15.47 | PEG | -0.95 |
| P/S | 2.69 | P/B | 1.88 | P/CF | 13.41 | P/FCF | 21.46 |
| Sales | $24.36B | Sales 1Y | -0.4% | Sales 3Y | -4.2% | Sales 5Y | 13.96% |
| EPS | $9.73 | EPS 1Y | -17.17% | EPS 3Y | -23.02% | EPS 5Y | -13.22% |
| Sales QoQ | 5.84% | EPS QoQ | -25.66% | Sales QoQ Avg | 0.89% | EPS QoQ Avg | 13.96% |
| Gross Margin | 58.69% | Operating Margin | 19.68% | Profit Margin | 11.22% | ROCE | 9.34% |
| ROA | 5% | ROE | 8% | Altman Z Score | 3.03 | Piotroski Score | 6 |
| Current Ratio | 1.69 | Quick Ratio | 1.09 | Cash Ratio | 0.24 | Op. CF Ratio | 0.07 |
| Debt/Equity | 0.41 | Debt/Assets | 0.23 | Lt Debt/Equity | 0.37 | Lt Debt/Cap. | 0.26 |
| Intrst Cov. | 8.52 | Inventory Turnover | 1.79 | Asset Turnover | 0.4 | Receivables Turnover | 4.31 |
| Enterprise Value | $84.21B | P/E Ratio | 16.28 |
| Forward P/E | 15.47 | PEG Ratio | -0.95 |
| P/S Ratio | 2.69 | P/B Ratio | 1.88 |
| P/CF Ratio | 13.41 | P/FCF Ratio | 21.46 |
| EPS | $9.73 | EPS Growth 1Y | -17.17% |
| EPS Growth 3Y | -23.02% | EPS Growth 5Y | -13.22% |
| Revenue Growth 1Y | -0.4% | Gross Margin | 0.59% |
| Operating Margin | 0.2% | Profit Margin | 0.11% |
| ROE | 0.08% | ROA | 0.05% |
| ROCE | 0.09% | Current Ratio | 1.69 |
| Quick Ratio | 1.09 | Cash Ratio | 0.24 |
| Debt/Equity | 0.41 | Interest Coverage | 8.52 |
| Altman Z Score | 3.03 | Piotroski Score | 6 |
Merck KGaA (MRK.DE) valuation & financials
Merck KGaA (MRK.DE) has a market capitalization of 68.80B EUR and trades at a price-to-earnings ratio of 16.3. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Merck KGaA's revenue grew -0.4% over the last year.
Merck KGaA's next earnings report is scheduled for November 12, 2026; analysts estimate EPS of 2.40 EUR. Check the earnings calendar to see all companies reporting this week.
Merck KGaA (MRK.DE) — frequently asked questions
When does Merck KGaA (MRK.DE) report earnings next?
Merck KGaA is expected to report earnings on November 12, 2026. Analysts estimate EPS of 2.40 EUR.
What is Merck KGaA's market cap?
Merck KGaA (MRK.DE) has a market capitalization of 68.80B EUR.
What is MRK.DE's P/E ratio?
Merck KGaA trades at a price-to-earnings ratio of 16.3, with trailing twelve-month EPS of 9.73 EUR.
How fast is Merck KGaA growing?
Merck KGaA's revenue grew -0.4% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)